Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Noxopharm Ltd. ( (AU:NOX) ) has shared an update.
Noxopharm Limited announced that its lupus medication, SOF-SKN™, has successfully passed crucial preclinical safety tests, moving it closer to the HERACLES clinical trial. The tests, including those for genotoxicity and cardiac toxicity, were conducted under international standards, ensuring the drug’s safety and paving the way for subsequent clinical trials. This achievement marks a significant step in Noxopharm’s development process, potentially enhancing its positioning within the biotech industry and signaling progress for stakeholders.
More about Noxopharm Ltd.
Noxopharm Limited is an innovative Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company employs proprietary technology platforms, Chroma™ and Sofra™, to enhance mRNA vaccines and develop new drugs for oncology, inflammation, and autoimmunity. Noxopharm also holds a major shareholding in Nyrada Inc., which specializes in novel small molecule therapies.
YTD Price Performance: -3.23%
Average Trading Volume: 146,242
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$26.3M
Learn more about NOX stock on TipRanks’ Stock Analysis page.
